Moleculin Biotech

65 articles with Moleculin Biotech

• Moleculin Announces its Sponsored Research at MD Anderson Cancer Center Has Resulted in the Filing of Patent Protection for New Discovery

  9/16/2019

  Moleculin Biotech, Inc. announced its sponsored research at MD Anderson Cancer Center has resulted in the filing of a new patent on behalf of MD Anderson Cancer Center covering the combination of its immune-stimulating/transcriptional-modulator, WP1066, with well-known immune checkpoint inhibitors.

• Moleculin Announces CTRC Approval of WP1066 Pediatric Brain Tumor Trial

  8/20/2019

  The trial will take place at the Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta.

• Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2019

  8/16/2019

  Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the second quarter ended June 30, 2019.

• Moleculin Announces Completion of Lymphoma Trial Enrollment

  8/13/2019

  Announced its proof of concept clinical trial to evaluate its p-STAT3 inhibitor, WP1220, for the topical treatment of Cutaneous T-Cell Lymphoma (CTCL) has reached full enrollment.

• Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models

  8/6/2019

  Data to be presented at the Inaugural Conference on Brain Metastases, August 16-17, 2019

• Moleculin Announces Annamycin in Acute Myeloid Leukemia in Poland Advances to 3rd Cohort

  7/18/2019

  Moleculin Biotech, Inc., announced additional positive interim safety and efficacy data from its ongoing open label, single arm Phase 1/2 study of Annamycin in Poland.

• Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2019

  5/14/2019

  Moleculin Biotech, Inc. announced its financial results for the first quarter ended March 31, 2019.

• Moleculin Announces Additional Positive Interim Results in First Cohort of Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia in Europe

  5/7/2019

  2 of 3 patients qualify to proceed to a potentially curative bone marrow transplant; trial advances to next higher dose level

• US Biopharma Company Undertakes Anti-Cancer Clinical Trials in Poland, First Patient Showing Positive Initial Treatment - April 29, 2019

  4/29/2019

  Moleculin quickly recruited qualified patients and started trials for two of its portfolio drugs to supplement US efforts.

• US Biopharma Company Undertakes Anti-Cancer Clinical Trials in Poland, First Patient Showing Positive Initial Treatment

  4/25/2019

  Moleculin quickly recruited qualified patients and started trials for two of its portfolio drugs to supplement US efforts.

• Moleculin Announces $15.0 Million Registered Direct Offering

  4/23/2019

   Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it has entered into definitive agreements with institutional investors to purchase an aggregate of 9,375,000 units at a public offering price of $1.60 per unit in a registered direct offering

• Moleculin Announces Conference Call to Discuss Significant Discovery For Lung Cancer and FDA Activity on Wednesday, April 24, 2019

  4/22/2019

  Moleculin Biotech, Inc. announced it will host a conference call to discuss its significant discovery for lung cancer, FDA Fast Track Designation and recent corporate events.

• Moleculin Receives FDA Approval of Fast Track Designation for Annamycin

  4/18/2019

  Moleculin Biotech, Inc., announced that the U.S. Food and Drug Administration has approved its request for Fast Track Designation for its drug, Annamycin, for the treatment of relapsed or refractory acute myeloid leukemia.

• Moleculin Announces Significant Discovery in Lung Cancer Models

  4/17/2019

  Annamycin Found to be Active Against Metastatic Lung Cancer in Pre-Clinical Testing

• Moleculin Announces Agreement with Emory University to Conduct Pediatric Brain Tumor Trial

  4/11/2019

  Moleculin Biotech, Inc. announced it has entered into an agreement with Emory University to conduct a Phase 1 clinical trial of WP1066 in children with recurrent or refractory malignant brain tumors.

• Moleculin Announces Successful Expansion of its Leukemia Drug Program

  4/9/2019

  Moleculin Biotech, Inc. announced it has successfully expanded the clinical supply of Annamycin for its on-going clinical trials via BSP Pharmaceuticals S.p.A. in Latina, Italy.

• Moleculin Announces Preclinical Pancreatic Cancer Data Presented at American Association for Cancer Research Annual Meeting

  4/3/2019

  Moleculin Biotech, Inc. announced that preclinical data supporting activity of its STAT3-inhibiting Immune/Transcription Modulators was presented by Dr. Waldemar Priebe, Founder and Chair of the Scientific Advisory Board of Moleculin, Inc. at the 2019 Annual Meeting of the American Association for Cancer Research ("AACR") in Atlanta, GA.

• 

  Houston: One of the Fastest-Growing Life Science Communities

  4/3/2019

  A recent report by CBRE Research analyzing U.S. life science clusters, found that Houston, Texas is the third-fastest growing life science market from 2014 to 2017. One doesn’t typically think of Texas, let alone Houston, as being a center for the life sciences. Oil, energy and tech, yes, but not...

• Moleculin Announces Pricing Of Underwritten Public Offering

  3/27/2019

  Each unit is comprised of one share of common stock and 0.5 of a warrant to purchase one share of common stock for a total of 5,250,000 shares of common stock and warrants to purchase 2,625,000 shares of common stock.

• Moleculin Announces Proposed Underwritten Public Offering

  3/26/2019

  Moleculin Biotech, Inc. announced that it intends to offer and sell units consisting of shares of common stock and warrants in an underwritten public offering.